Jump to content
  • Sign Up
  • rrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    We have completed two surveys with our members and general public.  These surveys were developed with the input of our RRDi Medical Advisory Consultants, and consists of questions of most concern to these doctors when diagnosing rosacea and based upon last year's survey. The more members respond to the survey, the more accurate and complete will be our picture of the rosacea experience of our extensive community, so your input is highly valued by the RRDi.

    To review our survey results click here

    We appreciate your continued support of the RRDi in helping to find a cure for rosacea.

    Thanks very much for your participation.

    Brady Barrows
    RRDi Director

    Joanne Whitehead, Ph.D.
    RRDi Assistant Director
    RRDi Journal Editor in Chief

  • Member Statistics

    1,345
    Total Members
    499
    Most Online
    ChemistsWorld
    Newest Member
    ChemistsWorld
    Joined
  • Forum Statistics

    • Total Topics
      4,627
    • Total Posts
      6,542
  • Posts

    • Related ArticlesStatPearls Book. 2020 01 Authors: Abstract Rosacea is a common chronic inflammatory disease that presents with recurrent flushing, erythema, telangiectasia, papules, or pustules on nose, chin, cheeks, and forehead. There are four clinical subtypes of rosacea based on the predominant signs and symptoms: erythematotelangiectatic, papulopustular, phymatous, and ocular. The subtypes are not mutually exclusive. Patients can present with features of multiple subtypes, and the predominant features and areas of involvement can change over time. Fifty to seventy-five percent of patients with rosacea have eye involvement with symptoms including dryness, redness, tearing, tingling/burning sensation, foreign-body sensation, light sensitivity, and blurred vision. In addition to the skin and eye symptoms, rosacea can cause anxiety, embarrassment, and depression and can have a significant impact on the quality of life. Although usually limited to the skin, an association of rosacea with systemic comorbidities such as neurologic diseases, inflammatory bowel disease, and cardiovascular diseases has been reported.[1][2][3][4] PMID: 32491506 {url} = URL to article
    • Related ArticlesAssessment of the abdominal fat index by ultrasonography in patients with rosacea. Australas J Dermatol. 2020 Jun 03;: Authors: Özkur E, Bülbün G, Karataş D, Kıvanç Altunay İ PMID: 32491195 [PubMed - as supplied by publisher] {url} = URL to article
    • "A variety of repurposed drugs and investigational drugs such as remdesivir, chloroquine, hydroxychloroquine, ritonavir, lopinavir, interferon‐beta, and other potential drugs have been studied for COVID19 treatment. We reviewed the potential dermatological side‐effects of these drugs." Dermatol Ther. 2020 May 22 : e13476.doi: 10.1111/dth.13476 [Epub ahead of print] Cutaneous sıde‐effects of the potential COVID‐19 drugs Ümit Türsen, Belma Türsen, Torello Lotti 
    • There are different approaches offered by the various 'authorities' on rosacea diagnosis into phenotypes. [1] However, they all agree that the phenotype classification is superior to the subtype classification that has been used since 2002 initially proposed by the NRS 'expert' panel. [2] The general consensus is "at least one diagnostic or two major phenotypes are required in order to diagnose a patient with rosacea." [3] {1} Diagnostic Cutaneous Signs (only one required) The ROSCO panel list includes persistent centrofacial erythema associated with periodic intensification by potential trigger factors as a minimum diagnostic feature of rosacea and phymatous changes are individually diagnostic of rosacea.  Fixed centrofacial erythema, papules and pustules, flushing or blushing, phymatous changes are included in the NRS panel diagnostic list.  Dr. Tan with the ROSCO panel, as well as the NRS Panel, and Dr. Del Rosso with the AARS panel both concur that facial erythema is essential to a diagnosis of rosacea. [4] OR {2} RRDi Phenotypes (two required) (1) Flushing (2) Persistent Erythema (3) Telangiectasia (4) Papulopustular (Papules/pustules Lesion Counts) (5) Phymatous (6) Ocular Manifestations Variances in Phenotype Listings The ROSCO panel has no numbering phenotype system but lists the above phenotypes.  The NRS 'expert' committee's approach has no numbering system and divides four phenotypes with three secondary phenotypes. [5] Galderma tweets four major phenotypes and four minor phenotypes.  The AAD follows the NRS expert panel recommendations.  The AARS has its own way of acknowledging the phenotype classification into six phenotypes:  "central facial erythema without papulopustular (PP) lesions;"  "central facial erythema with PP lesions;"  "the presence of phymatous changes," "ocular signs, and symptoms;"  "extensive presence of facial telangiectasias;"  "and marked, persistent, nontransient facial erythema that remains between flares of rosacea and might exhibit severe intermittent flares of acute vasodilation (flushing of rosacea)"  Medscape recognizes four major phenotypes and three secondary phenotypes following the NRS recommendations End Notes [1] ROSCOE Panel • NRS Expert Panel • Galderma • AAD • AARS • Medscape [2] Phenotype Treatment is Superior [3]  Clinical, Cosmetic and Investigational Dermatology February 2020 [4] Phenotype Classification Uses Signs and Symptoms Better [5] The four phenotypes the NRS lists are Papules and Pustules, Flushing, Telangiectasia, and  Ocular manifestations. The secondary phenotypes are  Burning or stinging, Edema, and Dry Appearance.  Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. 
×
×
  • Create New...